Direct Meds Reviews: NAD+ at $249 a Month, $199 on 90 Days

The one-sentence version

Direct Meds sells NAD+ at $249 a month for 500 mg and $299 for 1000 mg on a 30-day supply, or $199 and $249 a month if you take a 90-day supply shipped at once, with no membership and the clinician review inside the price³. Its headline, "As low as $199," is the 90-day rate. The price structure is genuinely clean; the billing story is less so, and so is the pharmacy story, because two Direct Meds pages name two different compounding sections. It grades A, 14 out of 14, tied for the highest score here.

What it is, and who it's for

Direct Meds is a compounded telehealth operator best known for GLP-1s, which also runs an Anti-Aging category of its own: NAD+ injection at two strengths, sermorelin injection, and a peptide skin cream. A one-minute qualifier is followed by payment for the first month, then a telehealth visit and a clinician review "expected… within 24 hrs and often less than 5 hrs." It holds LegitScript certification and publishes a medical director described as "a practicing physician [who] has reviewed our doctor and pharmacy network."

The buyer this suits wants a compounded protocol with no membership and no access fee, at one published monthly price. See longevity clinics vs lab memberships.

What it actually costs

NAD+, on the order page. The NAD+ product page offers two supplies at each strength. For 500 mg: "30 DAY SUPPLY $249.00 / month" and "90 DAY SUPPLY $199.00 / month · 21% OFF · 90-Day Supply Shipped At Once. Billed Monthly." For 1000 mg: $299 a month on a 30-day supply and $249 a month on a 90-day supply, with one 90-day option reading "$699.00 Total At Checkout Then $699.00 Every 3 Months." The page header reads "As low as $299.00 $199.00", which is the 90-day rate on 500 mg.

GLP-1s, for reference. Its FAQ says "Plans start at $249/month for sublingual Semaglutide, and $297/month for injections."

What the monthly figure covers. "Your medication, doctor review, pharmacy compounding, supplies, and 2-day shipping." Telehealth visits are inside it and are priced separately at "normally $99/visit." There is no membership and no access fee, and dose increases do not reprice the plan — "same price, every dose."

Plan on recurring billing, whatever the FAQ says. A Direct Meds FAQ answer reads "no surprise charges or automatic billing. Reorder at your convenience through your Direct Meds Patient Portal." The order page itself says "Billed Monthly" on both supplies, and one 90-day option charges "$699.00 Every 3 Months." The banner beside it reads "No Hidden Fees · No Monthly Membership · Cancel Anytime," and cancellation is by email or phone with no contract on month-to-month pricing. Ask how your plan renews before you pay, and set a reminder to cancel if you want to stop.

If you are declined, you are refunded. "If for any reason your prescription is not approved, you will receive a full refund." Note the sequence: you pay for the first month before the intake is reviewed.

Clinical oversight, and the pharmacy problem

Prescriptions follow a telehealth visit with a licensed provider in your state, and Direct Meds publishes nursing staff as a stage of the program — "on-going care & support with Direct Meds Nursing Staff" — which is why it takes the human-support point. Our grading methodology sets that out.

The pharmacy is where it goes wrong, and the fault is specific. The GLP-1 offer page states: "Medications prescribed through Direct Meds are dispensed by U.S.-based 503A compounding pharmacies." The NAD+ page — the page you would actually buy this product from — states: "Medications prescribed through Direct Meds are dispensed by U.S.-based 503B compounding pharmacies… 503B compounding pharmacies are licensed by state pharmacy boards and operate under federal compounding laws."

Those are different regimes, and the NAD+ page's description of the one it names is wrong: 503B outsourcing facilities register with FDA and must comply with current good manufacturing practice; being licensed by a state board of pharmacy is the 503A arrangement¹. Either the NAD+ line is a copy error or the two product lines use different facilities, and a buyer cannot tell which. What is not in doubt is that neither page names a pharmacy, and that compounded drugs of either class are not FDA-approved — "FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"¹.

The FDA warning letter, in proportion

On 9 September 2025, FDA's Center for Drug Evaluation and Research issued a warning letter to directmeds.com, Inc. dba DirectMeds (MARCS-CMS 716822)². That is the entity name verbatim from the letter's recipient block, and it doubles as the citation: search that string in the [FDA's warning-letter database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) and the letter is the first result you see. FDA's index carries no close-out date against it, so it remains open.

We report that the letter exists, who it names, and when it issued — and stop there. Restating the allegations would be us making the accusation; naming the addressee and the date is us reporting that the FDA made one, which is the only one of the two we are entitled to do on a page that earns a commission from the company. FDA's own copy is a search away and is the source worth reading.

The entity FDA named is the one behind the domain, so there is no question of a similarly-named company being confused for this one. Its scope is worth stating because omitting it would mislead in the other direction: the letter concerns the compounded weight-loss line, not the NAD+ or sermorelin products this review grades. It does not move the grade, and that is a rule rather than a favor: our rubric scores published terms — price, consult, pharmacy disclosure, support and longevity line — and a regulatory factor introduced after seeing which rows it would hit is a rule written to fit a result. Two other providers here hold letters of their own, reported identically and on the same reasoning: see our Sprout Health review and Strut Health review.

It belongs beside the section above rather than filed away from it. The pharmacy contradiction and the warning letter are independent findings about the same underlying thing — how carefully this company describes what it dispenses — and a reader weighing $199 a month is entitled to see them together.

The evidence behind what it sells

The NAD+ page is the most aggressive marketing in our ranking. It promises "Start Aging Backwards," the "fountain of youth peptide," and — as a heading — "Scientifically Proven to Help You Feel Younger, Sharper, and More Alive." Beneath that: "Improve Memory & Focus," "Revitalize Cellular DNA," "support long-term longevity," "~100% bioavailability," and results "Fast — feel energy & clarity in days… starting with your very first dose."

None of that is backed by human research. NAD+ supplements reliably raise NAD+ levels, but better energy, memory or strength in healthy adults has not followed, and injected NAD+, the entire product on this page, has not been tested for these claims at all.

The sermorelin line has the same problem: it raises growth hormone, but that has not been shown to change muscle or fat in healthy older adults. See NAD+ for longevity, peptides for longevity and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if the marketing is what sold you — "scientifically proven" is not a defensible sentence about this molecule. Skip it if the pharmacy classification matters to you, because Direct Meds gives two answers. And do not budget from the $99: your second month is $199, or $249 if your provider puts you on 1000 mg.

Two operational notes. Service is unavailable in Mississippi, and the compounding disclosure adds Louisiana. And the longevity line is buried: the Anti-Aging catalog lists NAD+ and sermorelin with no prices at all, and the figures live only on a separate funnel page.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Direct Meds takes all of them. One all-in figure per product is published with what it covers named; NAD+ and sermorelin are a real longevity line rather than a GLP-1 shop with a badge; the telehealth visit is inside the price; nursing support is published as part of the program; and a 503A claim appears on a surface it controls. Fourteen out of fourteen. An A.

That grade measures published terms, and it is worth saying what it does not measure. The headline is the 90-day rate, the FAQ and the order page disagree about automatic billing, two funnel pages disagree about which compounding regime fills your prescription, and the NAD+ copy promises outcomes no completed trial has produced. Buy it for what it verifiably is — a published monthly price with no membership — and budget the 30-day price unless you are ready to take three months at once. The full graded field is at our provider rankings; its immediate neighbors are our HealthRX review and RxSpan MD review.